🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion

    Partner Therapeutics Limited

    Extensive-disease small cell lung cancer and high SLFN11-expression

    phase 2 small molecule active

    1 trial

  2. IMP1734

    Eikon Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  3. INCAGN02385, Retifanlimab (INCMGA00012), INCAGN02390

    Incyte

    In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN.

    phase 2 small molecule active

    1 trial

  4. INDOCYANINE GREEN

    Fondazione Telethon ETS

    Patients with gynecological cancers undergoing pelvic exenteration

    phase 2 small molecule active

    1 trial

  5. INDV-6001

    Indivior Pty Ltd

    Moderate to Severe Opioid Use Disorder

    phase 2 small molecule completed

    1 trial

  6. INF904

    InflaRx GmbH

    Moderate to Severe Chronic Spontaneous Urticaria (CSU) or Moderate to Severe Hidradenitis Suppurativa (HS)

    phase 2 small molecule active

    1 trial

  7. INT230-6

    INTENSITY THERAPEUTICS, INC.

    Breast Cancer

    phase 2 small molecule active

    2 trials

  8. INXN-2001

    Alaunos Therapeutics

    Melanoma

    phase 2 mab completed

    1 trial

  9. INZ-701

    Lacuna Pharma Pty Ltd

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency and ATP-binding cassette sub-family C member 6 (ABCC6) Deficiency, Generalized Arterial Calcification of Infancy (GACI), Pseudoxanthoma elasticum (PXE)

    phase 2 small molecule active

    1 trial

  10. IONIS-FB-LRx

    IONIS PHARMACEUTICALS INC

    Macular Degeneration

    phase 2 small molecule completed

    1 trial

  11. IOV-3001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  12. IOV-4001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial

  13. IPN10200 placebo, DYSPORT 300 UNITES SPEYWOOD, poudre pour solution injectable, IPN10200

    Ipsen

    Treatment of Moderate to Severe Upper Facial Lines

    phase 2 small molecule active

    1 trial

  14. IR Viloxazine

    SUPERNUS PHARMACEUTICALS, INC.

    Attention-Deficit/Hyperactivity Disorder (ADHD)

    phase 2 small molecule completed

    1 trial

  15. IRINOTECAN, FOLINIC ACID, FLUOROURACIL, DOMVANALIMAB, FLUOROURACIL, ZIMBERELIMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    stomach cancer, Esophage, gastro-oesophageal junction adenocarcinoma

    phase 2 small molecule active

    1 trial

  16. ISIS 702843

    IONIS PHARMACEUTICALS INC

    Polycythemia Vera

    phase 2 small molecule active

    1 trial

  17. IV Remodulin

    United Therapeutics Europe Ltd

    Persistent Pulmonary Hypertension of the Newborn

    phase 2 small molecule terminated

    1 trial

  18. IW-1701

    Cyclerion Therapeutics

    Sickle Cell Disease

    phase 2 small molecule completed

    1 trial

  19. IW-1973

    Cyclerion Therapeutics

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  20. Ibrutinib

    United Therapeutics Europe Ltd

    Asymptomatic COVID-19 Infection Laboratory-Confirmed

    phase 2 small molecule terminated

    1 trial

  21. Ibrutinib

    Karyopharm Therapeutics Inc

    Lymphoma

    phase 2 small molecule active

    1 trial

  22. Ibrutinib 560 mg

    United Therapeutics Europe Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  23. Ibuprofen

    United Therapeutics Europe Ltd

    Tonsillectomy

    phase 2 small molecule completed

    1 trial

  24. Ibuprofen-PC

    Protalix BioTherapeutics

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources